PTCT Q2 2019 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+24.4% YoY

Gross Profit

$82M96.2% margin

Operating Income

-$39M-45.3% margin

Net Income

-$42M-48.9% margin

EPS (Diluted)

$-0.75

QoQ Revenue Growth

+59.6%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$44M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$803M

Stockholders' Equity

$489M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$69M	+24.4%
Gross Profit	$82M	$66M	+24.4%
Operating Income	-$39M	-$6M	-595.3%
Net Income	-$42M	-$10M	-339.0%

Revenue Segments

Product

$85M100%

Grant And Collaboration

$46,0000%